The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics

Current Opinion in Pharmacology
Kevin Mullane, Michael Williams

Abstract

Alzheimer's disease (AD) was differentiated from senile dementia (SD) in 1910 due to its early onset and pathological severity. In 1976, this distinction was upended when SD was redesignated as AD to focus efforts and funding in dementia-related research. AD then became conflated with amyloid plaques and, to a lesser degree, neurofibrillary tangles complicating efforts in understanding dementia causality and its treatment. The resultant four-decade search for therapies-based almost exclusively on amyloid was an exercise in futility. While dementia is a complex, multifactorial syndrome, AD is viewed as a homogeneous, linear disease. An amyloid-agnostic approach is necessary to discover therapeutics for age-related dementias.

Citations

Feb 26, 2019·Current Protocols in Pharmacology·Kevin Mullane, Michael Williams
Jul 9, 2020·Molecular Neurobiology·Maricarmen Hernández-RodríguezMartha Cecilia Rosales-Hernández
Feb 11, 2020·Biochemical and Biophysical Research Communications·Valery M DembitskyVladimir D'yakonov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Expert Review of Neurotherapeutics
Stella Karantzoulis, James E Galvin
Turkish Journal of Medical Sciences
Dursun Aygün, Ibrahim Levent Güngör
The Tohoku Journal of Experimental Medicine
Tetsuya SuharaMichie Miyoshi
Alzheimer's & Dementia : the Journal of the Alzheimer's Association
M Kathryn JedrziewskiJohn Q Trojanowski
© 2022 Meta ULC. All rights reserved